Get the Stockscreener App
35.32
0.51%
-0.18
Alkermes Plc stock is traded at $35.32, with a volume of 976.11K.
It is down -0.51% in the last 24 hours and up +17.34% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$35.50
Open:
$35.79
24h Volume:
976.11K
Relative Volume:
0.63
Market Cap:
$5.74B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
18.11
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
-1.59%
1M Performance:
+17.34%
6M Performance:
+24.98%
1Y Performance:
+21.04%
1-Day Range:
$35.09
$35.79
1-Week Range:
$35.09
$36.45
52-Week Range:
$22.90
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
35.32 | 5.74B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Hussman Strategic Advisors Inc. Invests $1.93 Million in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes plc (NASDAQ:ALKS) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Alkermes plc VP Samuel Joseph Parisi sells $47,360 in stock By Investing.com - Investing.com South Africa
Alkermes plc VP Samuel Joseph Parisi sells $47,360 in stock - Investing.com India
Van ECK Associates Corp Acquires 32,581 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes (NASDAQ:ALKS) Hits New 12-Month HighWhat's Next? - MarketBeat
Craig C. Hopkinson Sells 144,419 Shares of Alkermes plc (NASDAQ:ALKS) Stock - MarketBeat
Alkermes (NASDAQ:ALKS) Price Target Raised to $32.00 - MarketBeat
Opioid Use Disorder Treatment Market Size in the 7MM was around - openPR
Vontobel Holding Ltd. Sells 7,982 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes (NASDAQ:ALKS) Receives "Neutral" Rating from HC Wainwright - MarketBeat
Alkermes (NASDAQ:ALKS) Rating Increased to Strong-Buy at StockNews.com - MarketBeat
HC Wainwright Issues Negative Estimate for Alkermes Earnings - MarketBeat
Alkermes (NASDAQ:ALKS) Announces Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat
Alkermes (NASDAQ:ALKS) Updates FY 2025 Earnings Guidance - MarketBeat
Alkermes Plc EPS Soars Past Forecasts - AOL
Alkermes plc Just Beat EPS By 12%: Here's What Analysts Think Will Happen Next - Yahoo Finance
How to Take Advantage of moves in (ALKS) - Stock Traders Daily
Alkermes targets $310M-$340M adjusted EBITDA amid LYBALVI growth and orexin pipeline expansion - MSN
Alkermes (NASDAQ:ALKS) Earns Buy Rating from Analysts at Deutsche Bank Aktiengesellschaft - MarketBeat
Alkermes plc. Officer Sells Shares Worth Over $11 Million - TradingView
Earnings call transcript: Alkermes Q4 2024 beats EPS forecasts, stock rises - MSN
Alkermes Reaches Analyst Target Price - Nasdaq
Regulatory Challenges Pose Significant Risks to Alkermes’ Financial Stability - TipRanks
Alkermes plc Reports Record Revenues in 2024 Earnings Call - TipRanks
Alkermes price target raised to $32 from $30 at Goldman Sachs - TipRanks
Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up - MSN
Alkermes Shares Climb Amid Strong Earnings and Growth Prospects - TipRanks
Alkermes (NASDAQ:ALKS) Sets New 1-Year High on Earnings Beat - MarketBeat
Alkermes outlook reflects underlying strength, says H.C. Wainwright - TipRanks
Alkermes plc (NASDAQ:ALKS) Q4 2024 Earnings Call Transcript - Insider Monkey
Alkermes PLC (ALKS) Q4 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
Alkermes PLC (ALKS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Debt-Free Milestone - Yahoo Finance
Alkermes Plc earnings beat by $0.30, revenue topped estimates - Investing.com Nigeria
Alkermes plc Reports Strong 2024 Financial Results - TipRanks
Alkermes: Q4 Earnings Snapshot - Midland Daily News
Alkermes plc (ALKS) reports earnings - Quartz
Alkermes plc. SEC 10-K Report - TradingView
Alkermes plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Alkermes (ALKS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Alkermes plc Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Alkermes (ALKS) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alkermes Plc Stock (ALKS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 13 '25 |
Option Exercise |
30.12 |
144,419 |
4,350,097 |
202,294 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 12 '25 |
Option Exercise |
19.64 |
199,196 |
3,912,871 |
262,796 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 12 '25 |
Sale |
32.78 |
204,921 |
6,718,278 |
57,875 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Feb 13 '25 |
Sale |
35.53 |
144,419 |
5,130,698 |
57,875 |
0.99%
3.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):